Arch Oncology, Inc

4320 Forest Park Avenue
Suite 304
St. Louis
MO
63108
United States

Show jobs for this employer

About Arch Oncology, Inc

Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of cancer.  Anti-CD47 therapies represent a new class of checkpoint inhibitors that bridge the innate and adaptive immune systems to attack cancer. Arch Oncology has developed a functionally diverse antibody platform and is advancing a novel anti-CD47 antibody to the clinic that not only acts as an immune checkpoint inhibitor, but also selectively kills tumor cells (non ADCC).  The team is a highly motivated group of experienced scientists and emphasizes a collaborative approach. Arch Oncology is funded by top-quality venture capital investors and is advancing its lead mAb to the clinic currently.

Currently there are no articles for this employer.

Check out their jobs by clicking the "Show Jobs" button to the left.